Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 204

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 204
---
 have a majority of the voting power;

•

the Combined Company’s board is expected to consist of three directors, two of whom can be designated by Liminatus and one of whom can be designated by Iris;

•

all of Liminatus’s existing management will continue in their key positions in the management team of the Combined Company; and

•

Liminatus’s operations prior to the Business Combination comprise the ongoing operations.

#### Basis of Pro Forma Presentation
The unaudited pro forma combined financial information has been prepared in accordance with Article 11 of Regulation S-X. The adjustments in the unaudited pro forma combined financial information have been identified and presented to provide relevant information necessary for an illustrative understanding of the Combined Company upon consummation of the Business Combination and the other events contemplated by the Business Combination Agreement in accordance with GAAP.

Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma combined financial information are described in the accompanying notes. The unaudited pro forma combined financial information has been presented for illustrative purposes only and is not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the dates indicated, and does not reflect adjustments for any anticipated synergies, operating efficiencies, tax savings or cost savings. Any cash proceeds remaining after the consummation of the Business Combination and the other events contemplated by the Business Combination Agreement are expected to be used for general corporate purposes. Further, the unaudited pro forma combined financial

<div align='center'>89</div>

TABLE OF CONTENTS

information does not purport to project the future operating results or financial position of the Combined Company following the consummation of the Business Combination. The unaudited pro forma adjustments represent management’s estimates based on information available as of the date of the unaudited pro forma combined financial information and are subject to change as additional information becomes available and analyses are performed. The unaudited pro forma combined financial information contained herein assumes that the Iris stockholders approve the Business Combination. Pursuant to the Iris Certificate of Incorporation, the Iris public stockholders may elect to redeem their Iris common shares upon the closing of the Business Combination for cash equal to their pro rata share of the aggregate amount on deposit (as of two business days prior to the Closing) in the Trust Account. Iris cannot predict how many of its public stockholders will exercise their right to redeem their Iris common stock for cash. Therefore, the unaudited pro forma combined financial